John DiPersio, MD, PhD, on the future of blood cancers
In this SOHO Insider interview from the 2026 AACR Annual Meeting, John DiPersio, MD, PhD, president of the Society of Hematologic Oncology, shares
AACR 2026
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Video Interviews
Multiple Myeloma
News
Singapore’s HSA approves NDA for CAR-T therapy eque-cel in relapsed or refractory myeloma
Eque-cel, an anti-BCMA CAR-T, has been approved in China for treating patients with relapsed or refractory myeloma who have progressed after at least
SOHO 2026
Trending now
Meetings / Conferences
News
Society Updates
Grab your SOHO t-shirts during SOHO 2026!
Your contributions fund vital programs that accelerate progress in hematologic malignancies. Visit soho.click/donate to join the initiative.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
AACR 2026
Acute Lymphoblastic Leukemia
News
Video Interviews
Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement
Nicholas R. Pannunzio, PhD, of the Chao Family Comprehensive Cancer Center, discusses the underlying etiology of CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA accepts sBLA for mosunetuzumab and polatuzumab vedotin combo in relapsed or refractory large B-cell lymphoma
The submission is supported by findings from the phase III SUNMO trial evaluating the subcutaneous formulation of mosunetuzumab alongside intravenous polatuzumab vedotin for
Multiple Myeloma
News
China NMPA approves supplemental application for generic denosumab
Developed by Mabwell's wholly owned subsidiary T-mab, this new clearance specifically covers the use of the drug in reducing severe skeletal-related complications like
Leukemia
Chronic Myeloid Leukemia
News
FDA grants fast track designation to STX-0712 in relapsed or refractory CMML
The investigational Cytotoxicity Targeting Chimera targets the CCR2 receptor, highly expressed on malignant monocytes and bone marrow blasts to selectively eliminate disease-driving cells.
ASCO 2026
Lymphoma
Aggressive B-Cell Lymphomas
Meetings / Conferences
News
Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL
At the 2026 ASCO Annual Meeting, Marc Hoffman, MD, of the University of Kansas Cancer Center, discusses results from the ongoing GOLSEEK-1 trial
ASCO 2026
Trending now
Multiple Myeloma
SOHO Insider Podcast
Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma
Dr. Usmani and Mina discuss the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously
ASCO 2026
Trending now
Meetings / Conferences
Multiple Myeloma
News
Dr. Hans Lee on MRNA-2808 in relapsed or refractory multiple myeloma
Hans Lee, MD, director of Myeloma Research at the Sarah Cannon Research Institute, discusses an early phase 1/2 clinical trial evaluating the investigational